Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Roche RHHBY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted ...

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant ...

Updated overall survival (OS) results – a key secondary endpoint – reinforce the significant benefit of the Itovebi TM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated ...

Finding showed the inavolisib-based regimen reduced the risk of disease progression or death by 57% compared with palbociclib and fulvestrant alone. The Food and Drug Administration (FDA) has ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and ...